Case Reports in Oncology 2011-Sep
Addition of bevacizumab to temsirolimus in kidney cancer patients.
只有注册用户可以翻译文章
登陆注册
链接已保存到剪贴板
关键词
抽象
Treatment of metastatic kidney cancer has changed dramatically in the past years with the use of VEGF-targeted therapies and mTOR inhibitors. However, resistance occurs. We report here two cases of patients who benefited, both on disease control and side effects, from the addition of bevacizumab to temsirolimus, after progression on the mTOR inhibitor alone.